Evolent Health: Truist Securities Maintains Buy, Raises PT to $16 from $14.

Evolent Health: Truist Securities Maintains Buy, Raises PT to $16 from $14.

On July 1, 2025, Truist Securities announced a significant update to its recommendation and price target for Evolent Health Inc. (NYSE: EVH). Despite a slight reduction in the price target, the brokerage firm maintained its 'Buy' rating, reflecting continued confidence in the company's growth potential.

The new price target has been set at $16.00, an increase from the previous target of $14.00. This adjustment follows a series of positive developments for Evolent Health, including a strong consensus rating from analysts and robust institutional investment inflows.

Truist Securities' latest update comes amid a positive trend in analyst recommendations. According to Marketbeat, fourteen research firms have given Evolent Health an average recommendation of 'Buy', with twelve analysts assigning a 'Buy' rating and one analyst assigning a 'Strong Buy' rating. The average 12-month target price among analysts is $17.79, indicating a bullish outlook on the stock's future performance.

The institutional investment landscape also shows strong support for Evolent Health. Vanguard Group Inc. increased its holdings in Evolent Health by 2.4% in the fourth quarter, while Eventide Asset Management LLC and Engaged Capital LLC also significantly boosted their stakes in the company. These developments underscore the growing belief in Evolent Health's potential for growth and profitability.

Despite the positive outlook, Evolent Health's recent earnings report showed a slight miss in earnings per share (EPS), with the company reporting $0.06 EPS for the quarter, falling short of analysts' consensus estimates of $0.08. However, the company's revenue of $483.65 million exceeded analyst estimates of $460.15 million, indicating strong operational performance.

In conclusion, Truist Securities' updated recommendation and price target for Evolent Health reflect the company's promising growth prospects and robust institutional support. While the company faces challenges in meeting earnings expectations, its strong revenue growth and positive analyst ratings suggest a bright future for investors.

References:
[1] https://www.marketbeat.com/instant-alerts/evolent-health-inc-nyseevh-receives-consensus-rating-of-buy-from-brokerages-2025-07-14/
[2] https://www.investing.com/news/analyst-ratings/first-industrial-realty-trust-stock-maintains-buy-rating-at-truist-securities-on-strong-q2-results-93CH-4139292